Sugi Predict

Sugi Predict / Compounds / SCHEMBL6035513

SCHEMBL6035513

SCHEMBL6035513

COc1cc(CO)cc(OCc2ccccc2)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 5/20 0.65
▸ MEN1 O00255 1/20 0.54
▸ KMT2A Q03164 1/20 0.54
▸ CYP4F2 P78329 1/20 0.53
▸ CYP4A11 Q02928 1/20 0.53
▸ ABCB1 P08183 3/20 0.52
▸ TSHR P16473 2/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ BCHE P06276 3/20 0.49
▸ MRGPRX4 Q96LA9 1/20 0.49
▸ LMNA P02545 1/20 0.49
▸ CYP1A2 P05177 1/20 0.49
▸ PTGS1 P23219 1/20 0.49
▸ SLC6A2 P23975 1/20 0.49
▸ CYP2C19 P33261 1/20 0.49
▸ PTGS2 P35354 1/20 0.49
▸ SLC6A3 Q01959 1/20 0.49
▸ HIF1A Q16665 1/20 0.49
▸ HDAC6 Q9UBN7 1/20 0.49
▸ RHEB Q15382 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4910012 0.91 MEN1 (0.62) MAOBMEN1KMT2ACYP4F2CYP4A11
SCHEMBL14601810 0.90 MEN1 (0.61) MAOBMEN1KMT2ACYP4F2CYP4A11
SCHEMBL23906959 0.89 MAOB (0.79) MAOBMEN1KMT2AABCB1TSHR
SCHEMBL24951300 0.88 MAOB (0.46) MAOBABCB1APP
SCHEMBL3271153 0.88 CYP4F2 (0.61) MAOBMEN1KMT2ACYP4F2CYP4A11
SCHEMBL6201670 0.87 MEN1 (0.54) MAOBMEN1KMT2ACYP4F2CYP4A11
SCHEMBL29961843 0.87 MAOB (0.56) MAOBCYP4F2CYP4A11ABCB1TSHR
SCHEMBL28893583 0.87 MAOB (0.56) MAOBCYP4F2CYP4A11ABCB1TSHR
SCHEMBL27939586 0.87 MAOB (0.65) MAOBMEN1KMT2AABCB1TSHR
SCHEMBL5791635 0.86 MAOB (0.69) MAOBMEN1KMT2AABCB1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11583507-B2 Direct AMPK activator compounds SOCIETE DES PRODUITS NESTLE S.A. (CH) 2023-02-21 — — US disclosed
US-11583507-B2 Direct AMPK activator compounds SOCIETE DES PRODUITS NESTLE S.A. (CH) 2023-02-21 — — US disclosed
EP-3968976-A1 PHENANTHRENE AMPK ACTIVATOR COMPOUNDS, COMPOSITIONS, METHODS AND USES THEREOF Société des Produits Nestlé S.A. (CH) 2022-03-23 — — EP disclosed
US-20220062199-A1 PHENANTHRENE AMPK ACTIVATOR COMPOUNDS, COMPOSITIONS, METHODS AND USES THEREOF NESTLE SA (CH) 2022-03-03 — — US disclosed
CN-113784708-A Phenanthrene AMPK activator compounds, compositions, methods, and uses thereof 雀巢产品有限公司 2021-12-10 — — CN disclosed
EP-3801475-A1 DIRECT AMPK ACTIVATOR COMPOUNDS Société des Produits Nestlé S.A. (CH) 2021-04-14 — — EP disclosed
US-20210038536-A1 DIRECT AMPK ACTIVATOR COMPOUNDS SOCIETE DES PRODUITS NESTLE S.A. (CH) 2021-02-11 — — US disclosed
US-20210038536-A1 DIRECT AMPK ACTIVATOR COMPOUNDS SOCIETE DES PRODUITS NESTLE S.A. (CH) 2021-02-11 — — US disclosed
CN-112203647-A Direct AMPK activator compounds 雀巢产品有限公司 2021-01-08 — — CN disclosed
WO-2020229375-A1 PHENANTHRENE AMPK ACTIVATOR COMPOUNDS, COMPOSITIONS, METHODS AND USES THEREOF Société des Produits Nestlé S.A. (CH) 2020-11-19 — — WO disclosed
WO-2020229375-A1 PHENANTHRENE AMPK ACTIVATOR COMPOUNDS, COMPOSITIONS, METHODS AND USES THEREOF Société des Produits Nestlé S.A. (CH) 2020-11-19 — — WO disclosed
WO-2019228794-A1 DIRECT AMPK ACTIVATOR COMPOUNDS SOCIETE DES PRODUITS NESTLE S.A. (CH) 2019-12-05 — — WO disclosed
WO-2019228794-A1 DIRECT AMPK ACTIVATOR COMPOUNDS SOCIETE DES PRODUITS NESTLE S.A. (CH) 2019-12-05 — — WO disclosed
US-9181186-B2 Aromatic ring compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-11-10 — — US disclosed
US-20150045378-A1 AROMATIC RING COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-02-12 — — US disclosed
EP-2816032-A1 AROMATIC RING COMPOUND Takeda Pharmaceutical Company Limited (JP) 2014-12-24 — — EP disclosed
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 — — US disclosed
EP-1513817-A1 1, 2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY Takeda Pharmaceutical Company Limited (JP) 2005-03-16 — — EP disclosed
WO-2003099793-A9 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL (JP) 2005-02-10 — — WO disclosed
WO-2003099793-A1 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-12-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150045378-A1 AROMATIC RING COMPOUND GPR119, GPR27, GPR4 MAOB 3876/4885MEN1 2985/4885KMT2A 2066/4885
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 MAOB 954/4885MEN1 2048/4885KMT2A 1706/4885
US-11583507-B2 Direct AMPK activator compounds PRKAG2, AK2, PRKAG3 MAOB 3811/4885MEN1 2096/4885KMT2A 1673/4885
US-20210038536-A1 DIRECT AMPK ACTIVATOR COMPOUNDS PRKAG2, AK2, PRKAG3 MAOB 3811/4885MEN1 2096/4885KMT2A 1673/4885
US-20220062199-A1 PHENANTHRENE AMPK ACTIVATOR COMPOUNDS, COMPOSITIONS, METHODS AND USES THEREOF PRKAG2, PRKAG1, PRKAG3 MAOB 3790/4885MEN1 2856/4885KMT2A 1208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.